Physiomics (AIM: PYC) has provided a positive operational update, highlighting record commercial opportunities, cost savings and a clearer path towards profitability as the AIM-listed modelling and data science specialist executes its growth strategy.
The company said it is building the largest commercial pipeline in its history, providing a strong platform for future revenue growth. Directors reported encouraging levels of engagement from both existing and prospective clients and expect to provide further updates on contract wins in the coming weeks.
Following changes to the board earlier this year, Physiomics acknowledged it incurred one-off costs related to the extraordinary general meeting at which the previous directors were removed. However, management said it has already identified operational cost savings that are expected to outweigh those exceptional expenses, with most of the benefits being realised during the next financial year.
An independent strategic review by consultant Stewart Williams also endorsed the business, with the board stating that most of the recommended improvements have already been implemented.
The company has also completed a review of its IT infrastructure and operational systems, concluding that the business is well equipped to support larger and more complex customer projects while maintaining high service standards as it scales.
Looking ahead, Physiomics expects to provide further updates on commercial progress, including developments relating to its Predict-Onc and DoseMe platforms, alongside a more detailed strategic review in its forthcoming annual report.
Director Ian Bagnall said the company has identified a robust financial strategy aimed at moving the business towards breakeven. Combined with revenues already secured and anticipated near-term commercial activity, he believes Physiomics has established the foundations for a more sustainable and financially resilient business.
Overall, the update points to improving operational momentum, a strengthening sales pipeline and a disciplined focus on cost control as Physiomics positions itself for future growth.

